All In Biotech

NDA 204426 · Apil

Taytulla

Ethinyl Estradiol, Norethindrone Acetate · Oral

Last checked: Nov 20, 2026Latest source record: Jun 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Apr 19, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

501

113 Phase 3, 20 recruiting

FAERS reports

318

73 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications (4) and Warnings & Precautions (5.1) ] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See Full Prescribing Information for complete boxed warning. Women over 35 years old who smoke should not use TAYTULLA. ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 4 )

What it is approved for

From the label in effect Oct 25, 2024.

1 INDICATION S AND USAGE TAYTULLA is indicated for use by females of reproductive age to prevent pregnancy [ see Clinical Studies (14) ] . The efficacy of TAYTULLA in women with a body mass index (BMI) of more than 35 kg/m 2 has not been evaluated. TAYTULLA is a combination of norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy ( 1 ) The efficacy of TAYTULLA in females of reproductive potential with a body mass index (BMI) of > 35 kg/m 2 has not been evaluated ( 1 , 8.8 )

Mechanism: CHCs lower the risk of becoming pregnant primarily by suppressing ovulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TAYTULLA · ETHINYL ESTRADIOL 0.02MG; NORETHINDRONE ACETATE 1MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethinyl Estradiol" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use45
  • drug ineffective34
  • recalled product administered34
  • nausea20
  • pregnancy20
  • headache16
  • metrorrhagia16
  • product dose omission13
  • pruritus13
  • anxiety11
  • dizziness9
  • pregnancy on oral contraceptive9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20124
20165
201717
201893
201996
202048
202127
20229
20238
20245
20256

Recalls

1 FDA enforcement reports for this application.

  • May 24, 2018 · Class I · Terminated

    Contraceptive Tablets Out of Sequence.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Taytulla (Norethindrone-E.Estradiol-Iron)

2024 spending

$19K

Beneficiaries

n/a

45 claims

Per beneficiary

n/a

$8.55 per unit

View as table
YearSpending
2020$74,891
2021$29,927
2022$29,828
2023$30,374
2024$19,163

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,068 on PubMed

Sponsor: Apil

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.